| 1 |
35527497 | [The dual mTORC1/2 inhibitor AZD2014 inhibits acute graft rejection in a rat liver transplantation model]. | 2022 Apr 20 |
2 |
| 2 |
34308856 | [Antitumor effects of AZD2014, a dual mTORC1/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice]. | 2021 Jul 20 |
2 |
| 3 |
34543871 | First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial. | 2021 Nov |
2 |
| 4 |
34560229 | Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth. | 2021 Dec 28 |
2 |
| 5 |
34674743 | AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo. | 2021 Oct 21 |
3 |
| 6 |
32601986 | The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory. | 2020 Sep |
1 |
| 7 |
31100427 | Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia. | 2019 Jul 27 |
1 |
| 8 |
31286402 | An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells. | 2019 Oct |
1 |
| 9 |
31385336 | A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. | 2019 Oct |
1 |
| 10 |
31465093 | Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. | 2019 Nov 1 |
1 |
| 11 |
31519585 | mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both In Vitro and In Vivo. | 2019 Sep |
1 |
| 12 |
29898401 | Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. | 2018 Jun 12 |
1 |
| 13 |
30587022 | Comparative toxicity evaluation of targeted anticancer therapeutics in embryonic zebrafish and sea urchin models. | 2018 Dec |
1 |
| 14 |
28885497 | Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection. | 2017 Dec |
1 |
| 15 |
29371953 | Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. | 2017 Dec 26 |
1 |
| 16 |
27031247 | AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest. | 2016 |
2 |
| 17 |
25444920 | Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma. | 2015 Feb 28 |
2 |
| 18 |
25628925 | Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. | 2015 |
4 |
| 19 |
26219339 | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | 2015 Jul 10 |
2 |
| 20 |
26358751 | AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. | 2015 Nov |
4 |
| 21 |
24309100 | Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. | 2014 Jan 10 |
2 |
| 22 |
24311635 | The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. | 2014 Jan |
2 |
| 23 |
25190803 | Unspliced X-box-binding protein 1 (XBP1) protects endothelial cells from oxidative stress through interaction with histone deacetylase 3. | 2014 Oct 31 |
1 |